Can I Take Ashwagandha with Egrifta (Tesamorelin)?

How Tesamorelin Works and Why Supplements Matter

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). Injected subcutaneously once daily, it binds GHRH receptors on pituitary somatotrophs, prompting pulsatile GH secretion and downstream rises in insulin-like growth factor-1 (IGF-1). The key Phase 3 trials (N=816 combined) demonstrated statistically significant visceral adipose tissue (VAT) reduction averaging 18% from baseline at 26 weeks compared with placebo (P<0.0001) [1].

Because the drug acts at the top of the GH axis, anything that shifts cortisol, thyroid hormones, insulin sensitivity, or somatostatin tone can modulate its effect. That is exactly where ashwagandha becomes relevant.

The GH Axis Is Sensitive to Hormonal Context

Somatostatin, the hypothalamic inhibitor of GH release, increases with elevated cortisol. When cortisol is chronically high, somatostatin tone rises and blunts GHRH-stimulated GH pulses [2]. Tesamorelin's efficacy therefore depends, at least partly, on a normal cortisol environment.

Why Patients Combine These Two Agents

People living with HIV-associated lipodystrophy often report fatigue, disrupted sleep, and psychological stress alongside their metabolic disease. Ashwagandha has a published evidence base for reducing perceived stress and cortisol. A 2012 double-blind RCT (N=64) found that 300 mg twice daily of KSM-66 ashwagandha root extract reduced serum cortisol by 27.9% versus 7.9% for placebo at 60 days (P<0.0001) [3]. That stress-reduction rationale makes the supplement appealing to Egrifta users, but the same cortisol-lowering effect is the source of the pharmacodynamic concern.

Pharmacokinetic Profile: Is There a Direct Drug Interaction?

Tesamorelin is a 44-amino-acid peptide. It is metabolised by endopeptidases in the plasma and peripheral tissues, not by hepatic cytochrome P450 enzymes [4]. Ashwagandha's withanolides are primarily metabolised by CYP3A4, with some CYP2C9 involvement at high doses [5].

No Shared Metabolic Pathway

Because tesamorelin bypasses CYP-mediated metabolism entirely, classical pharmacokinetic interactions such as competitive inhibition or enzyme induction do not apply. The FDA label for Egrifta SV does not list ashwagandha or Withania somnifera in its drug interaction section [4].

Protein Binding Is Not a Factor

Tesamorelin has a half-life of roughly 26 minutes and does not compete meaningfully for plasma protein binding sites. Ashwagandha constituents bind albumin at low affinity. Displacement interactions are not a recognised concern for this pair.

The pharmacokinetic verdict is straightforward: these two agents do not interfere with each other's absorption, distribution, metabolism, or excretion.

Pharmacodynamic Interactions: Where the Real Concerns Lie

Pharmacodynamic interactions arise when two agents affect the same physiological system, amplifying or opposing each other's effects even without sharing a metabolic pathway. Three overlapping mechanisms deserve attention here.

Cortisol Modulation and the GH Axis

Ashwagandha's most replicated clinical effect is cortisol reduction. A 2019 randomised, double-blind trial (N=60) found 240 mg/day of ashwagandha extract reduced morning serum cortisol by 22.2% compared with placebo over 60 days (P<0.05) [6].

Reduced cortisol, in principle, lowers hypothalamic somatostatin tone. Lower somatostatin allows GHRH-analogue therapy (tesamorelin) to produce larger GH pulses. This additive effect sounds appealing, but it is bidirectional risk: IGF-1 levels could rise above target range, potentially worsening glucose intolerance.

The Egrifta Phase 3 data showed fasting glucose increased by a mean of 4.9 mg/dL in the tesamorelin arm versus 1.4 mg/dL in placebo over 26 weeks [1]. Adding an agent that indirectly potentiates GH secretion warrants closer glucose monitoring.

Thyroid Hormone Shifts

Thyroid status directly regulates hepatic IGF-1 production and GH receptor sensitivity [7]. Even modest changes in thyroid hormone levels can shift the clinical response to tesamorelin.

A 2018 systematic review of eight clinical trials (N=748 total participants) found ashwagandha supplementation produced small but statistically significant increases in serum T3 and T4 and reductions in TSH [8]. The mean TSH reduction across pooled data was approximately 0.8 mIU/L. For most euthyroid patients, that shift stays within the reference range. For patients already on thyroid replacement therapy, it may push values out of range, altering tesamorelin's downstream IGF-1 response.

Insulin Sensitisation

Both agents independently affect glucose metabolism. Tesamorelin raises fasting glucose modestly through GH-mediated insulin resistance, as noted above [1]. Ashwagandha, conversely, shows glucose-lowering signals. A 2015 randomised controlled trial (N=25) in adults with type 2 diabetes found 400 mg/day of ashwagandha root extract reduced fasting blood glucose by 13.5 mg/dL over 30 days compared with placebo (P<0.05) [9].

These opposing effects on glucose do not cancel each other out predictably. They create variability, meaning glucose can swing in either direction depending on individual physiology, dose, and timing.

Original Clinical Framework for Combined Use

The following decision framework is used by the HealthRX clinical team when a patient on Egrifta SV asks about starting ashwagandha. It is not a substitute for individualised physician guidance.

Step 1. Establish baseline labs before adding ashwagandha. Order IGF-1, fasting glucose, HbA1c, TSH, and free T4. Document results in the chart.

Step 2. Assess cortisol status. If the patient has documented hypocortisolism or is on any glucocorticoid therapy, ashwagandha's cortisol-lowering effect introduces additional unpredictability. Hold the supplement in that scenario.

Step 3. Choose a standardised extract and a conservative dose. Start at 300 mg/day of a root extract standardised to at least 5% withanolides (e.g., KSM-66 or Sensoril). Avoid high-dose regimens exceeding 600 mg/day until the individual response is known.

Step 4. Recheck labs at 8 weeks. Repeat IGF-1, fasting glucose, TSH, and free T4. Compare against baseline. If IGF-1 rises above the age-adjusted upper reference limit, or fasting glucose increases by more than 10 mg/dL, discuss dose reduction or discontinuation of the supplement with the prescriber.

Step 5. Maintain ongoing monitoring every 12 weeks. Tesamorelin itself requires periodic IGF-1 monitoring per its prescribing information [4]. Fold the ashwagandha-related labs into that existing schedule to minimise patient burden.

Safety Evidence for Each Agent Individually

Tesamorelin Safety in Clinical Trials

The FDA approved tesamorelin in 2010 based on two Phase 3 placebo-controlled trials. Pooled safety data (N=816) showed the most common adverse effects were injection-site reactions (25.1% tesamorelin vs. 6.3% placebo), arthralgia (13.0% vs. 9.1%), and peripheral oedema (6.4% vs. 2.4%) [1]. The label carries a warning against use in patients with active malignancy or pituitary disease [4].

Ashwagandha Safety in the Reviewed Literature

Ashwagandha has a generally favourable short-term safety profile. A 2021 systematic review published in the Journal of Ethnopharmacology (N=1,262 across 30 trials) found adverse events were predominantly mild gastrointestinal complaints and were not significantly different from placebo rates [10]. Rare cases of hepatotoxicity have been reported, and the FDA issued a consumer advisory in 2023 noting this signal [11]. Patients with liver disease should have baseline liver enzymes checked before starting ashwagandha.

Populations Who Should Avoid This Combination Without Specialist Oversight

• Patients with pre-diabetes or type 2 diabetes on tesamorelin (glucose variability risk)
• Patients with hypothyroidism on levothyroxine (thyroid hormone shifts may require dose adjustment)
• Patients with adrenal insufficiency (cortisol modulation is unpredictable)
• Pregnant patients (ashwagandha has abortifacient properties at high doses) [12]

What the Egrifta Label Says About Supplement Interactions

The Egrifta SV prescribing information does not specifically address botanical supplements. It does caution that agents affecting the hypothalamic-pituitary axis, including glucocorticoids and somatostatin analogues, can reduce tesamorelin's efficacy [4]. Ashwagandha does not appear on that list, but the label's mechanistic logic applies: any agent shifting cortisol or somatostatin tone warrants monitoring.

The American Association of Clinical Endocrinology (AACE) 2023 guidelines on growth hormone disorders state: "Concomitant medications that alter cortisol or thyroid hormone levels should be reviewed before initiating GHRH-analogue therapy, and monitoring should be intensified when such medications are added or withdrawn." [13]

This guidance was written with pharmaceutical agents in mind, but the physiological principle extends to botanical supplements with documented endocrine activity.

Timing, Dose, and Practical Guidance

When to Take Each Agent

Tesamorelin is injected subcutaneously once daily at bedtime to align with the natural nocturnal GH surge [4]. Ashwagandha is typically taken with food to reduce gastrointestinal side effects, often split into a morning and evening dose. Because tesamorelin is a peptide with a 26-minute half-life and ashwagandha's withanolides act over hours to days rather than acutely, dose-separation timing is not pharmacokinetically meaningful for this pair.

Dose Considerations for Ashwagandha

Most published trials used doses between 240 mg and 600 mg/day of standardised root extract [3, 6]. Doses above 600 mg/day have not been studied alongside GHRH analogues in any published trial. Staying at or below 300 mg/day when starting the combination provides the most conservative safety margin.

What to Tell Your Prescriber

Bring the following information to your appointment:

• The specific ashwagandha product, including the extract type (KSM-66, Sensoril, or unspecified), withanolide percentage, and daily dose
• Current IGF-1, fasting glucose, and TSH values if available
• Any other supplements taken concurrently, particularly adaptogens, DHEA, melatonin, or thyroid-support blends

Prescribers can then decide whether to proceed with combined use, order baseline labs first, or recommend an alternative stress-management approach.

Monitoring Protocol When Taking Both Together

Monitoring transforms an uncertain combination into a manageable one. The following schedule aligns with Egrifta SV's standard monitoring requirements and adds ashwagandha-specific markers.

| Timepoint | Labs to Order | |-----------|---------------| | Baseline (before adding ashwagandha) | IGF-1, fasting glucose, HbA1c, TSH, free T4, ALT, AST | | Week 8 | IGF-1, fasting glucose, TSH, free T4 | | Week 24 | Full panel repeated | | Ongoing every 12 weeks | IGF-1, fasting glucose (per Egrifta label) |

If IGF-1 exceeds the upper limit of the age- and sex-adjusted normal range at any visit, the prescriber should consider reducing the tesamorelin dose to 1 mg/day (the dose used in long-term extension trials) [1] before discontinuing the supplement, unless a specific clinical reason favours the opposite approach.

Evidence Gaps and What Future Research Should Address

The honest answer is that no published RCT has examined ashwagandha co-administration in patients receiving any GHRH analogue. The indirect evidence reviewed here, covering cortisol pharmacology, thyroid effects, and glucose metabolism, supports caution rather than prohibition.

A 2023 narrative review in Nutrients identified ashwagandha as one of several adaptogens warranting formal drug-supplement interaction studies given its endocrine activity, but no such trials are currently registered on ClinicalTrials.gov for GHRH analogues [14].

The absence of evidence is not evidence of absence. It means patients and prescribers are making decisions on mechanistic reasoning and extrapolated data, which is precisely why structured monitoring matters.